Advancing mitochondrial medicine
About Santhera

About


Santhera


We are a Swiss specialty pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.
________

Read more >>

PATIENTS


About mitochondrial diseases


At Santhera, we are passionate about providing treatment options for patients with rare mitochondrial diseases, specifically in the area of neuromuscular and neuro-ophthalmological conditions – diseases that have a severe impact on the lives of affected children and adults.
________

Read more >>
home-picture-01
Our medicines

Health Care Professionals


Our medicines



Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. In September 2015, we received our first European Marketing Authorization for Raxone® in the treatment of patients with Leber’s hereditary optic neuropathy.

________

Read more >>

Investors & Media


Tools and Resources



The Investor and Media center provides information and resources for investor and media communities.

________

Read more >>
Tools and Resources
Working at Santhera

Career


Working @Santhera



Santhera is a dynamic and international employer looking for colleagues who are talented, engaged and committed to growing the organization through the work that they do.

________

Read more >>

Join our Feeds

news

Latest News

January 20, 2017
Santhera to Report 2016 Preliminary Key Financial Figures and Provide Corporate Update on January 26, 2017
Read morepdf-icon
Santhera informiert am 26. Januar 2017 über wichtigste Finanzkennzahlen 2016 und die aktuelle Unternehmensentwicklung
Mehr dazupdf-icon


December 23, 2016
Santhera’s Raxone® designated Promising Innovative Medicine (PIM) and suitable candidate for further evaluation under the UK Early Access to Medicines Scheme (EAMS) for treatment in Duchenne muscular dystrophy
Read morepdf-icon
Santheras Raxone® als Promising Innovative Medicine (PIM) und geeigneter Kandidat für weitere Prüfung im Rahmen des UK Early Access to Medicines Scheme (EAMS) zur Behandlung von Duchenne-Muskeldystrophie anerkannt
Mehr dazupdf-icon


November 8, 2016
Swissmedic Accepts for Review Santhera’s Marketing Authorization Application for Raxone® for the Treatment of Duchenne Muscular Dystrophy
Read morepdf-icon
Swissmedic prüft Santheras Zulassungsantrag für Raxone® zur Behandlung von Duchenne-Muskeldystrophie 
Mehr dazupdf-icon



Earlier press releases can be found here.
To subscribe to our News Feed, please click here.



June 1, 2016


 

June 21, 2016


 

June 21, 2016

facebook

Facebook

linkedin

Linked In

This section of the website is intended to provide healthcare professionals with information about Raxone® and other products in Santhera’s pipeline. I am a healthcare professional I am not a healthcare professional